Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24179838 | 0.89 | GHSR (0.45) | GHSRPRSS1PRSS2PRSS3F2 | |
| SCHEMBL20964468 | 0.87 | KIFC1 (0.43) | GHSRPRSS1PRSS2PRSS3F2 | |
| SCHEMBL20964465 | 0.85 | PRSS1 (0.54) | PRSS1PRSS2PRSS3CTSL | |
| SCHEMBL20964423 | 0.85 | PRSS1 (0.61) | GHSRPRSS1PRSS2PRSS3CTSL | |
| SCHEMBL24179837 | 0.83 | PSMB5 (0.52) | GHSRPRSS1PRSS2PRSS3PSMB5 | |
| SCHEMBL20964467 | 0.83 | GPR139 (0.60) | PRSS1PRSS2PRSS3CTSL | |
| SCHEMBL24179824 | 0.82 | PRSS1 (0.54) | PRSS1PRSS2PRSS3CTSL | |
| SCHEMBL20964477 | 0.82 | CTSL (0.48) | GHSRSSTR3CTSL | |
| SCHEMBL20964424 | 0.82 | GHSR (0.55) | GHSRPRSS1PRSS2PRSS3PSMB5 | |
| SCHEMBL20964413 | 0.81 | PRSS1 (0.57) | GHSRPRSS1PRSS2PRSS3SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220526-B2 | Neuropeptide S receptor (NPSR) agonists | RESEARCH TRIANGLE INSTITUTE (US) | 2022-01-11 | — | — | US | disclosed |
| US-20190127419-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RESEARCH TRIANGLE INSTITUTE | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127419-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | NPSR1, GRPR, NPBWR1 | GHSR 14/4885PRSS1 195/4885PRSS2 395/4885 |
| US-11220526-B2 | Neuropeptide S receptor (NPSR) agonists | NPSR1, GRPR, NPBWR1 | GHSR 14/4885PRSS1 195/4885PRSS2 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.